NCT04191499 2026-03-17INAVO120Hoffmann-La RochePhase 2/3 Active not recruiting325 enrolled 14 charts 1 FDA
NCT02598661 2026-01-05Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)Geron CorporationPhase 2/3 Active not recruiting289 enrolled 35 charts 1 FDA
NCT03022825 2025-10-16QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder CancerImmunityBio, Inc.Phase 2/3 Active not recruiting190 enrolled 1 FDA
NCT03470922 2025-09-09RELATIVITY-047Bristol-Myers SquibbPhase 2/3 Active not recruiting714 enrolled 17 charts 1 FDA
NCT04145531 2023-11-18An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL)Jazz PharmaceuticalsPhase 2/3 Completed229 enrolled 17 charts 2 FDA
NCT01818492 2023-02-21Study to Investigate Safety, Efficacy of an Anti-IFNγ mAb in Children With Primary Haemophagocytic LymphohistiocytosisSwedish Orphan BiovitrumPhase 2/3 Completed45 enrolled 20 charts 1 FDA